Needham & Company Starts Rhythm Pharmaceuticals (RYTM) at Buy

October 30, 2017 7:01 AM EDT Send to a Friend
Needham & Company initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Buy rating and a price target of $32.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login